# SX-682

Source: https://onco.cc/drugs/sx-682/  
OnCo record `sx-682` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SX-682 is an experimental tablet from Syntrix Pharmaceuticals that blocks the CXCR1 and CXCR2 receptors on immune-suppressing cells. It is in phase 2 trials, alone or with other medicines, in prostate cancer, lung cancer and other cancers.

## Summary

SX-682 is Syntrix Pharmaceuticals' CXCR1/2 inhibitor. Registered trials in OnCo include NCT06228053, a Syntrix-sponsored phase 2 trial with enzalutamide in metastatic castration-resistant prostate cancer; NCT05570825 and NCT07322341, University of Washington trials with pembrolizumab and with atezolizumab in non-small cell lung cancer; and NCT06149481, a National Cancer Institute trial combining it with a vaccine, retifanlimab and N-803 in metastatic colorectal cancer. NCI SBIR awards to Syntrix in 2026 fund studies in myelodysplastic syndromes and melanoma.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-04
- Tags: pipeline
- Code: SX-682
- Modality: Oral small-molecule inhibitor
- Mechanism: A dual inhibitor of the chemokine receptors CXCR1 and CXCR2, which Syntrix Pharmaceuticals describes as inactivating the myeloid-derived suppressor cells and neutrophils that shield tumours from T cells and natural killer cells.

## Sources

- Syntrix Pharmaceuticals: SX-682: https://syntrixbio.com/pages/immuno-oncology/
- ClinicalTrials.gov: trials of SX-682: https://clinicaltrials.gov/search?intr=SX-682

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- companies: [Syntrix Pharmaceuticals](https://onco.cc/companies/syntrix-pharmaceuticals/)
- trials: [Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can](https://onco.cc/trials/nct06149481/), [Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer](https://onco.cc/trials/nct06228053/), [SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer](https://onco.cc/trials/nct07322341/), [SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05570825/)

---
JSON: https://onco.cc/api/v1/entities/sx-682.json